62results about How to "Dosing is simple" patented technology

A dosing device (17) for the medical administration of powder (16) through the nose or mouth has a valve body (27) which is movable in a discharge channel (22) between two valve seats (25, 26). During suction, the spherical valve body (27) is raised from the lower, container-sealing valve seat (26) and moved by a flow drag to the upper valve seat (25), so that it closes the discharge channel (22) and terminates dosing. The formation of the air / powder dispersion can be assisted in that the air subsequently sucked into the container is directed onto or into a powder supply or to a powder receiver in a pre-chamber fillable by tilting the device for pre-dosing.

Azalide antibiotics such as azithromycin are useful in the treatment and prevention of infections by bacteria and other parasites. Stabilized aqueous compositions containing azithromycin suitable for administration without reconstitution are provided for. Also provided for are aqueous formulations suitable for ocular administration in a employing a convenient dosing formulation suitable for administration in depot formats.

Dosing components (22, 24, 32) in an engine exhaust after-treatment system (18) that includes an SCR catalyst (20) are thermally managed by flowing engine coolant through a coolant passage in a urea injector (22) that injects aqueous urea into the after-treatment system, controlling a three-way valve (60) to selectively direct coolant flow leaving the urea injector to a first branch that is in heat exchange relationship with a tank (24) that holds a supply of aqueous urea and a supply pump module (32) that pumps aqueous urea from the tank to the urea injector, and a second branch that is not in heat exchange relationship with either the tank or the supply pump, and returning coolant from the branches to the engine cooling system.

A device for dosing and forming pods (1) containing a product for infusion and comprising a piece of filter material containing a dose of the product for infusion. The device comprises: a station (2) for feeding the product into at least one forming impression (3) defining a single dose of the product and made in means (4) for forming a respective compressed disk (5) of the infusion product and releasing the compressed disk (5) from the impression (3) in the filter material to form the pod (1).

Dosing components (22, 24, 32) in an engine exhaust after-treatment system (18) that includes an SCR catalyst (20) are thermally managed by flowing engine coolant through a coolant passage in a urea injector (22) that injects aqueous urea into the after-treatment system, controlling a three-way valve (60) to selectively direct coolant flow leaving the urea injector to a first branch that is in heat exchange relationship with a tank (24) that holds a supply of aqueous urea and a supply pump module (32) that pumps aqueous urea from the tank to the urea injector, and a second branch that is not in heat exchange relationship with either the tank or the supply pump, and returning coolant from the branches to the engine cooling system.

A device for administering an injectable product in doses, wherein the device includes a casing, a reservoir for the product, a piston, an advancing element which moves the piston a selected path length, and a dosing mechanism including a number of dosing bodies and a dosing element operable to move the dosing bodies, wherein the path length is selected by the dosing element moving at least one dosing body between the piston and the advancing element.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and / or premature ejaculation are described.

A device for dosing and forming pods (1) containing a product for infusion and comprising a piece of filter material containing a dose of the product for infusion. The device comprises: a station (2) for feeding the product into at least one forming impression (3) defining a single dose of the product and made in means (4) for forming a respective compressed disk (5) of the infusion product and releasing the compressed disk (5) from the impression (3) in the filter material to form the pod (1).

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and / or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

A flocculation-electroheterogeneous catalysis method for treating naphthenic acid wastewater. First, air flotation-flocculation treatment is carried out on naphthenic acid wastewater, the pressure is 0.2-0.4MPa, and the dosage of the agent is 0.01-0.07% of the wastewater volume; after the flocculation treatment, the DC voltage between the electrodes in the electric field is 5-15V, and the current Under an external electric field of 200-400 mA per square decimeter, the organic pollutants in the naphthenic acid wastewater are catalyzed and oxidized on the surface of the catalyst. The experimental results show that the combined technology can be used to treat naphthenic acid wastewater, which can be directly discharged up to the standard, and the operating cost is low.

The invention discloses a method for treating alkaline oily wastewater with a demulsifier, which adopts a secondary demulsification and two-stage air flotation treatment process. The main steps include: preparing a demulsifier, adding the demulsifier to a primary demulsification tank for Once fully stirred, through the first vortex air flotation treatment, the treated water enters the secondary demulsification tank for secondary demulsification, enters the air flotation tank for secondary dissolved air flotation treatment, and efficiently treats alkaline oily wastewater. The oil removal effect of the treatment method of the present invention can reach more than 95%; and the multifunctional agent of the present invention is low in price, easy to obtain on the market, easily soluble in water, simple to add, low in operating cost, obviously more stable in effect, and easy to use. practical use.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

An apparatus is proposed for the dosed dispensing of a fluid, especially an infusion fluid, comprising a housing (1) with a fluid chamber and a pressure medium chamber (3) by which a flexible wall (4) of the fluid chamber can be pressurized from the outside with a pressure medium. In order to provide a re-useable infusion pump with especially simple means it is proposed that the housing (1) consists of two mutually detachably joined housing parts (6, 7), of which the one comprises the pressure medium chamber (3) and the other receives in an exchangeable manner the fluid chamber configured as a leak-proof infusion bag (2), and that the housing part (6) with the pressure medium chamber (3) is sealed by a membrane (5) against the housing part (7) receiving the infusion bag (2) and is connected to a gas pressure source (11).

The present invention relates to therapeutic combinations of [9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, (−)-cis FTC, Emtriva™ and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and / or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of GS-7340 and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

A flocculation-electric multi-phase catalysis process for treating the sewage in oil field includes such steps as air floating-flocculating treatment of sewage under 2-4 Pa, adding catalyst 0.01-0.1%of sewage quantity, applying DC electric field with 5-10 V and 50-400 mA, and catalytic oxidization to organic pollutant in sewage. Its advantages are high effect and low cost.

The invention provides a crosslinking agent system, a low-concentration polymer crosslinked fracturing fluid and preparation methods of the crosslinking agent system and the low-concentration polymercrosslinked fracturing fluid. The low-concentration polymer crosslinked fracturing fluid has both high viscoelasticity of the existing polymer fracturing fluid and low damage of a clean fracturing fluid. The economical efficiency of the fracturing fluid is improved by means of low concentration, and accordingly, the low-concentration polymer crosslinked fracturing fluid is more popular with oilfields on the premise of cost decreasing, benefit increasing and reservoir protecting. A prepared base fluid has the viscosity range of 10-24 mPa.s, and is easy to prepare and pump. Delayed crosslinkingtime is 30-120 s, gel can be formed after crosslinking, viscosity is enhanced three times or more, sand carrying is facilitated, and a supporting agent can be delivered to the far end of a fracture. Therefore, the low-concentration polymer crosslinked fracturing fluid inherits various advantages of the traditional fracturing fluid, and further, the sand carrying capability and fracture conductivity of the fracturing fluid can be improved effectively.

A balloon brachytherapy applicator has either a single or double chambers, with the capability of “blistering” outwardly at a specified area on one side of the balloon. This is useful to move sensitive tissue, such as skin or bone, farther away from a radiation source within a source guide inside the balloon. In one case a secondary balloon or secondary compartment is formed on the primary balloon, and is separately inflatable so as to allow blistering as desired when needed. In another form the balloon comprises a single chamber, primarily of inelastic or fairly rigidly elastic wall material, but with a “window” or area in which the balloon wall is elastic, or substantially more elastic than the main balloon wall, so that inflation of the balloon up to a certain point forms a substantially regular balloon shape (which may be approximately spherical), and the addition of further pressure will blister out the elastic area to increase the distance between the shaft and the sensitive tissue in a desired orientation of the balloon.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

The invention provides an inorganic-organic composite profile control and water plugging agent and a use method thereof. The inorganic-organic composite profile control and water plugging agent is prepared from the following components in percentage by mass: 0.10 to 0.30 percent of temperature-resistant and salt-resistant polymer, 1.5 to 5.2 percent of silicon-containing compound, 0.2 to 0.5 percent of water-soluble surfactant, 0.55 to 1.25 percent of gelling time regulator, 0.25 to 0.65 percent of strength regulator, 0.10 to 0.30 percent of micro-nano particles and the balance of water. The profile control and water plugging agent provided by the invention can overcome the problems that the existing gel and gel profile control and water plugging agents are difficult to inject in an oil reservoir and the gelling time is uncontrollable, and realizes deep profile control and water plugging of the oil reservoir. The profile control and water plugging agent can be used for oil reservoirs with the temperature of 50-150 DEG C.

The invention discloses a nano-composite cross-linking agent for fracturing fluid and a preparation method of the nano-composite cross-linking agent, and relates to the technical field of fracturing fluid for oil and gas development. The cross-linking agent comprises a chelate synthesized by nano carbon quantum dots and metal ions. The invention further discloses the preparation method of the nano composite cross-linking agent for the fracturing fluid. The method comprises the following steps: step 1, preparing the nano carbon quantum dots; and step 2, adding inorganic salt of metal ions into the prepared nano carbon quantum dots, and performing reacting for 1.5-3 hours to obtain the nano cross-linking agent. The chelate formed by chelating the nano carbon quantum dots and the metal ions is adopted as the composite cross-linking agent, and the problems that existing fracturing fluid cross-linking agents are complex in component and complex in fluid preparation are solved. One carbon quantum dot of the cross-linking agent has a plurality of cross-linking points, so that more guanidine gum molecular chains can be cross-linked under the same addition amount; and the dispersity is better, and the carbon quantum dots have a reinforcing effect on the fracturing fluid, so that the guanidine gum fracturing fluid which is cross-linked by the cross-linking agent has a better temperature-resistant effect compared with existing cross-linking agents, and the temperature resistance can reach 180-200 DEG C.

The invention provides a household sewage treatment device of a circulating fluidized bed.The household sewage treatment device comprises an anaerobic reaction unit, an aerobic reaction unit and a filtering and precipitating unit.A water inlet is formed in the upper portion of the anaerobic reaction unit, and a stirring air pipe is arranged at the bottom of the anaerobic reaction unit.The aerobic reaction unit is filled with efficient biocompatibility filler.A filter material bearing plate is arranged at the lower portion of the filtering and precipitating unit, and a cover plate is arranged at the upper portion of the filtering and precipitating unit.The space between the filter material bearing plate and the cover plate is filled with a filter material.A water outlet is formed in the upper portion of the filtering and precipitating unit, and the bottom of the anaerobic reaction unit is communicated with the upper area of the filler cover plate of the aerobic reaction unit through a first connecting pipe.The bottom of the aerobic reaction unit is communicated with the lower area of the filter material bearing plate through a second communicating pipe.The upper portion of the anaerobic reaction unit is communicated with the lower area of the filter material bearing plate through a backflow pipe.The household sewage treatment device has the advantages of being high in sewage treatment efficiency, small in occupied area, capable of easily making the sewage treatment result to reach the standards and the like.

The invention relates to a method for removing organophosphorus amino trimethylene phosphonic acid in wastewater with a chemical precipitation method.Calcium hydroxide, an iron salt solution or an aluminum salt solution, and a flocculating agent solution are sequentially added into wastewater with organophosphorus ATMP, the removing rate of organophosphorus can be 97% or above, and the phosphorus concentration in the solution can be reduced to 0.5 mg / L or below.The method is easy and convenient to operate and low in cost, the concentration of total phosphorus of outlet water can be controlled at the low level, and the discharging standard of total phosphorus of effluent water is met.

The invention relates to a removal method for 2-phosphomobutane-1,2,4-tricarboxylic acid in organophosphorus-containing wastewater.The method comprises the steps that calcium hydroxide, ferric salt or aluminum salt and a flocculant solution are sequentially added into the wastewater containing organophosphorus 2-phosphomobutane-1,2,4-tricarboxylic acid, the removal rate of organophosphorus 2-phosphomobutane-1,2,4-tricarboxylic acid can reach 89% or above, and the concentration of phosphorus in the solution can be lowered to 0.5 mg / L or below.The method is easy and convenient to operate, low in cost and stable in operation, the total phosphorus concentration of effluent can be controlled to be in a low level, and the total phosphorus discharge standard of the effluent is met.

The invention relates to a compositing and compounding process for a bactericide for oilfield wastewater reinjection treatment. The compositing and compounding process comprises steps as follows: (1), hexamethylenediamine is added to a reaction kettle, the temperature is raised in a stirring state, and iminourea hydrochloride is added; (2), the temperature is raised continuously, a thermostatic reaction is performed, and meanwhile, hydrochloric acid is added dropwise to serve as a catalyst; (3), the temperature is raised continuously, and a thermostatic reaction is performed; (4), after the reaction is finished, water and hydrochloric acid are added and uniformly stirred, and a product generated in the reaction is polyhexamethyleneguanidine chloride; (5), polyhexamethyleneguanidine chloride, tetrakis hydroxymethyl phosphonium sulfate, a biquaternary ammonium salt bactericide, nonylphenol polyoxyethylene ether-10, methylisothiazolinone and water are added to a preparation kettle and fully stirred; (6), a sodium hydroxide solution is added, and a pH (potential of hydrogen) value is adjusted to range from 7 to 9. The process has the beneficial effects that the character is stable; adding is simple; various agents are compounded, so that the problem of bacterial resistance is solved; the purpose of quickly killing bacteria in waste through the bactericide with lower concentration is achieved.

The invention provides a preparation method for environment-friendly nanometer emulsion fracturing fluid. The method comprises the following steps of dissolving monomers A, monomers B, monomers C, inorganic salts and dispersing agents into deionized water to form a mixed solution; performing heating and nitrogen gas introduction; adding initiators to initiate the polymerization under the nitrogen gas protection; meanwhile, dispersing the mixed solution by using high-speed dispersion combining high-pressure homogenizing or high-pressure microjet to form dispersing liquid; diluting the dispersing liquid so as to obtain the environment-friendly nanometer emulsion fracturing fluid through preparation. The monomers A are water-soluble monomers with carbon-carbon double bonds; the monomers B are cationoid water-soluble monomers with carbon-carbon double bonds; the monomers C are polyether type monomers with carbon-carbon double bonds. The preparation method for the fracturing fluid is simple; the environment-friendly effect and no pollution are realized; the energy consumption is low; the application range is wide; meanwhile, the excellent functions of resistance reduction, clay stability, discharge assistance, sand suspending, surface activity reduction and the like are realized; high stability is realized; layering flocculation, accumulation and sedimentation cannot easily occur.

The invention provides a method for synchronously removing nitrate and phosphate in water by adopting a three-dimensional electrolysis device. A diaphragm-free electrolytic system is formed by takinga copper / graphene oxide modified titanium electrode plate as a cathode and taking a chlorine evolution electrode plate as an anode; and meanwhile, iron carbon is added into water to form a three-dimensional electrode of a three-dimensional electrode electrolysis system to electrolyze water. Under the action of the current of the electrodes, a large amount of nitrate nitrogen is reduced by utilizing the copper / graphene oxide modified titanium electrode plate, and zero-valent iron of iron-carbon microelectrolysis can also be used for reducing the nitrate nitrogen, wherein the reduction product is ammonia nitrogen; the chlorine evolution electrode is adopted as the anode, and chlorine ions are used as a supporting electrolyte to carry out oxidization at the anode to generate chlorine; then the chlorine is dissolved in water to generate strong oxidant hypochlorous acid, wherein the hypochlorous acid can oxidize the reduction product ammonia nitrogen of nitrates into nitrogen; meanwhile, iron ions generated during a process that the nitrates are reduced by iron elementary substance are precipitated with phosphorus; and further adsorption is conducted by activated carbon, so that the removal effect of total phosphorus is enhanced.

The present invention relates to industrial effluent treating technology, and is especially one kind of comprehensive cutting effluent treating technological method. The technological process includes the first air floatation-flocculation treatment in pressure of 0.2-0.4 MPa and flocculant consumption of 0.1-6 wt% of the effluent; subsequent ultrafiltration-reverse osmosis treatment including two-stage of microfilm filtering at 0.05-0.6 MPa and reverse osmosis at 0.5-1.5 MPa; and final electrical multiphase catalytic oxidation in the voltage 10-15 V and current density of 100-400 mA / sq dm and in the presence of supported catalyst with Fe or Mn oxide as the active component and in the amount of 1 / 5 to 5 / 6 of effluent volume. The present invention has the advantages of high effluent treating effect resulting in capacity of direct exhaust, low treatment cost, simple operation and no secondary pollution.